
Moderna leads with growing sales and promising cancer vaccine; BioNTech faces leadership changes and slower progress.
Moderna and BioNTech, once known for their COVID-19 vaccines, are shifting focus to cancer treatments. Moderna's stock has risen due to its personalized cancer vaccine showing strong trial results and growing revenue from multiple approved products, ...





